PROTHENA CORP PUBLIC LTD CO PRTA
Prothena Corporation plc ("Prothena" or the "Company") is a late-stage clinical biotechnology company with expertise in protein dysregulation with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases.
Fueled by its deep scientific expertise built over decades of research, the Company is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. The Company's pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS) and a number of other neurodegenerative diseases. Prothena is developing and applying its proprietary CYTOPE® technology to target a broad spectrum of intracellular disease pathways in the brain and periphery.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.7M | $135.2M | $91.4M | $53.9M | $200.6M | $853.0K | $814.0K | $955.0K | $27.5M | $1.1M |
| R&D | $134.9M | $222.5M | $220.6M | $135.6M | $82.3M | $74.9M | $50.8M | $101.2M | $134.5M | $119.5M |
| SG&A | $59.4M | $67.2M | $61.8M | $49.9M | $46.3M | $38.7M | $35.7M | $42.5M | $48.2M | $41.1M |
| Total operating expenses | $224.3M | $289.7M | $282.4M | $185.5M | $128.6M | $113.6M | $86.5M | $159.8M | $182.8M | $160.6M |
| Operating income | -$214.6M | -$154.6M | -$191.0M | -$131.6M | $72.0M | -$112.7M | -$85.7M | -$158.9M | -$155.3M | -$159.5M |
| Interest expense | $14.1M | $25.8M | $31.0M | $6.3M | $42.0K | $1.4M | $8.2M | $2.7M | $142.0K | $556.0K |
| Pre-tax income | -$200.8M | -$128.9M | -$160.5M | -$125.6M | $71.9M | -$111.4M | -$77.3M | -$156.1M | -$157.6M | -$159.0M |
| Income tax | $43.3M | $6.6M | $13.5M | $8.7M | $4.9M | $283.0K | $379.0K | $470.0K | $4.4M | $1.1M |
| Net income | -$244.1M | -$122.3M | -$147.0M | -$116.9M | $67.0M | -$111.1M | -$77.7M | -$155.6M | -$153.2M | -$160.1M |
| EPS, basic | -4.53 | -2.27 | -2.76 | -2.47 | 1.51 | -2.78 | -1.95 | — | — | — |
| EPS, diluted | -4.53 | -2.27 | -2.76 | -2.47 | 1.38 | -2.78 | -1.95 | -3.93 | -4.07 | -4.66 |
| Shares, diluted (wtd. avg.) | $53.8M | $53.8M | $53.2M | $47.4M | $48.5M | $39.9M | $39.9M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $307.5M | $471.4M | $618.8M | $712.6M | $580.4M | $298.1M | $378.4M | $431.7M | $421.7M | $391.0M |
| Receivables | — | $0 | $5.2M | $0 | $0 | $15.0K | $68.0K | $2.0K | $240.0K | $178.0K |
| Total current assets | $315.2M | $485.4M | $639.3M | $719.1M | $584.8M | $299.3M | $378.4M | $431.4M | $426.3M | $391.4M |
| Property, plant and equipment | $2.1M | $3.1M | $3.8M | $1.7M | $2.0M | $2.6M | $3.9M | $52.8M | $55.0M | $56.5M |
| Total assets | $326.8M | $547.1M | $696.4M | $758.0M | $609.4M | $333.0M | $419.3M | $498.8M | $496.3M | $460.0M |
| Accounts payable | $5.9M | $7.8M | $25.4M | $9.3M | $3.7M | $4.1M | $1.2M | $1.5M | $13.6M | $13.1M |
| Total current liabilities | $40.8M | $48.5M | $56.9M | $50.1M | $33.5M | $25.8M | $17.7M | $14.9M | $37.4M | $41.1M |
| Total liabilities | $46.3M | $60.2M | $135.0M | $136.0M | $143.3M | $149.0M | $146.3M | $175.8M | $89.1M | $94.6M |
| Retained earnings | -$1.35B | -$1.10B | -$980.0M | -$833.0M | -$716.1M | -$783.0M | -$671.9M | -$598.0M | -$442.4M | -$289.2M |
| Total equity | $280.5M | $486.9M | $561.4M | $622.0M | $466.0M | $184.0M | $272.9M | $323.0M | $407.2M | $365.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$163.6M | -$150.1M | -$133.9M | -$108.8M | $92.6M | -$80.4M | -$53.0M | -$28.3M | -$131.2M | -$116.2M |
| Depreciation and amortisation | $895.0K | $893.0K | $928.0K | $744.0K | $1.1M | $1.5M | $1.6M | $3.2M | $3.1M | $2.4M |
| Stock-based compensation | $37.6M | $46.0M | $40.9M | $31.3M | $24.7M | $22.0M | $23.6M | $27.0M | $26.8M | $24.9M |
| Investing cash flow | -$138.0K | -$298.0K | -$2.8M | -$464.0K | -$575.0K | -$196.0K | -$547.0K | -$1.7M | -$3.5M | -$16.6M |
| Financing cash flow | -$139.0K | $1.6M | $45.1M | $241.5M | $190.3M | $215.0K | $228.0K | $40.0M | $165.4M | $153.3M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001559053-26-000008.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |